News and Press

ACELYRIN, INC. Affibody AB, and Inmagene Biopharmaceuticals Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
December 14, 2021

Affibody AB, and Inmagene Biopharmaceuticals, today announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis (PsA) met its primary endpoint in a pre-specified interim analysis.

Read more
ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases
November 16, 2021

Series B led by AyurMaya, an affiliated fund of Matrix Capital Management, Surveyor Capital (a Citadel company), and Westlake Village BioPartners

Read more
ACELYRIN Announces Appointment of Patrick Machado, JD to Board of Directors
June 10, 2021

Mr. Machado has more than two decades of experience growing biopharmaceutical organizations from development through commercialization...

Read more
ACELYRIN Appoints Paul M. Peloso, MD, as Chief Medical Officer
May 25, 2021

ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development...

Read more
Load More